D. Boral Capital Reaffirms “Buy” Rating for Enlivex Therapeutics (NASDAQ:ENLV)

D. Boral Capital reiterated their buy rating on shares of Enlivex Therapeutics (NASDAQ:ENLV) in a research report released on Friday morning,Benzinga reports. They currently have a $13.00 price objective on the stock.

Enlivex Therapeutics Trading Up 6.8 %

Shares of ENLV opened at $1.10 on Friday. The firm has a 50-day moving average price of $1.18 and a 200 day moving average price of $1.29. Enlivex Therapeutics has a 52-week low of $0.81 and a 52-week high of $4.59.

Enlivex Therapeutics (NASDAQ:ENLV) last posted its quarterly earnings data on Friday, November 29th. The company reported ($0.12) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.16) by $0.04. As a group, sell-side analysts predict that Enlivex Therapeutics will post -0.7 EPS for the current year.

Institutional Trading of Enlivex Therapeutics

A hedge fund recently bought a new stake in Enlivex Therapeutics stock. Sigma Investment Counselors Inc. acquired a new position in Enlivex Therapeutics Ltd. (NASDAQ:ENLV) during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund acquired 30,000 shares of the company’s stock, valued at approximately $50,000. Sigma Investment Counselors Inc. owned about 0.14% of Enlivex Therapeutics at the end of the most recent reporting period. 1.02% of the stock is currently owned by institutional investors.

Enlivex Therapeutics Company Profile

Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial.